Edition:
United Kingdom

Cadila Healthcare Ltd (CADI.NS)

CADI.NS on National Stock Exchange of India

217.75INR
16 Aug 2019
Change (% chg)

Rs-0.25 (-0.11%)
Prev Close
Rs218.00
Open
Rs218.00
Day's High
Rs219.00
Day's Low
Rs214.75
Volume
1,616,550
Avg. Vol
2,403,086
52-wk High
Rs432.50
52-wk Low
Rs213.55

Latest Key Developments (Source: Significant Developments)

Cadila Healthcare Says U.S. FDA Classifies Co's Moraiya Facility As OAI
Wednesday, 7 Aug 2019 

Aug 7 (Reuters) - Cadila Healthcare Ltd ::GETS LETTER FROM U.S. FDA CLASSIFYING INSPECTION AT CO'S MORAIYA FACILITY AS 'OFFICIAL ACTION INDICATED' (OAI).CLASSIFICATION WILL NOT HAVE ANY IMPACT ON CURRENT SUPPLIES OR REVENUES OF FACILITY.IN PROCESS OF SENDING FURTHER UPDATES OF ITS CORRECTIVE ACTIONS TO U.S. FDA.  Full Article

Cadila Healthcare Says U.S. FDA Inspects Co's API Manufacturing Facility At Ankleshwar
Friday, 26 Jul 2019 

July 26 (Reuters) - Cadila Healthcare Ltd ::SAYS USFDA INSPECTED CO'S API MANUFACTURING FACILITY LOCATED AT ANKLESHWAR.SAYS AT END OF INSPECTION, NO OBSERVATION (483) IS ISSUED.  Full Article

India's Cadila Healthcare March-Qtr Consol Net Profit Falls
Wednesday, 29 May 2019 

May 29 (Reuters) - Cadila Healthcare Ltd ::MARCH QUARTER CONSOL NET PROFIT 4.6 BILLION RUPEES VERSUS PROFIT OF 5.91 BILLION RUPEES LAST YEAR.MARCH QUARTER CONSOL SALES 36.2 BILLION RUPEES VERSUS 31.53 BILLION RUPEES LAST YEAR.RECOMMENDED DIVIDEND OF 3.5 RUPEES PER SHARE.  Full Article

Cadila Healthcare Says USFDA Inspection At Moraiya Formulations Manufacturing Facility Ended With 14 Observations
Friday, 3 May 2019 

May 3 (Reuters) - Cadila Healthcare Ltd ::USFDA INSPECTED COMPANY'S FORMULATIONS MANUFACTURING FACILITY AT MORAIYA, AHMEDABAD FROM 22ND APRIL 2019 TO 3RD MAY 2019.SAYS INSPECTION CONCLUDED WITH 14 OBSERVATIONS.THERE WERE NO REPEAT OBSERVATIONS OR DATA INTEGRITY RELATED OBSERVATIONS.  Full Article

Cadila Healthcare Says Zydus & Sifi To Launch Intraocular Lenses In India
Tuesday, 30 Apr 2019 

April 30 (Reuters) - Cadila Healthcare Ltd ::SAYS ZYDUS AND SIFI FROM ITALY ANNOUNCE MARKETING ALLIANCE TO LAUNCH INNOVATIVE INTRAOCULAR LENSES IN INDIA.  Full Article

India's Cadila Healthcare Says Zydus Gets U.S FDA Final Approval For Leflunomide Tablets
Thursday, 25 Apr 2019 

April 25 (Reuters) - Cadila Healthcare Ltd ::SAYS ZYDUS RECEIVES FINAL APPROVAL FROM U.S FDA FOR LEFLUNOMIDE TABLETS USP.  Full Article

Cadila Healthcare Says Zydus Gets Final USFDA Nod For Lurasidone Hydrochloride Tablets
Friday, 22 Mar 2019 

March 22 (Reuters) - Cadila Healthcare Ltd ::ZYDUS RECEIVES FINAL APPROVAL FROM THE USFDA FOR LURASIDONE HYDROCHLORIDE TABLETS.LURASIDONE HYDROCHLORIDE TABLETS WILL BE MANUFACTURED AT GROUP'S MANUFACTURING FACILITY AT SEZ, AHMEDABAD.MEDICATION USED TO TREAT CERTAIN MENTAL/MOOD DISORDERS SUCH AS SCHIZOPHRENIA, DEPRESSION ASSOCIATED WITH BIPOLAR DISORDER.  Full Article

Cadila Healthcare Says Zydus Receives Final Approval From U.S FDA For Potassium Chloride Extended-Release Capsules
Wednesday, 13 Mar 2019 

March 13 (Reuters) - Cadila Healthcare Ltd ::ZYDUS RECEIVES FINAL APPROVAL FROM USFDA FOR POTASSIUM CHLORIDE EXTENDED-RELEASE CAPSULES USP.SAYS DRUG WILL BE MANUFACTURED AT THE GROUP’S FORMULATIONS MANUFACTURING FACILITY AT SEZ, AHMEDABAD .  Full Article

Cadila Healthcare Says Zydus Gets Final USFDA Approval For Atenolol And Chlorthalidone Tablets
Tuesday, 12 Mar 2019 

March 12 (Reuters) - Cadila Healthcare Ltd ::SAYS ZYDUS RECEIVES FINAL APPROVAL FROM USFDA FOR ATENOLOL AND CHLORTHALIDONE TABLETS USP.DRUG WILL BE MANUFACTURED AT THE GROUP’S FORMULATIONS MANUFACTURING FACILITY AT SEZ, AHMEDABAD.  Full Article

Cadila Healthcare Says Zydus Gets USFDA Final Approvals For Phytonadione, Colchicine Tablets
Thursday, 21 Feb 2019 

Feb 21 (Reuters) - Cadila Healthcare Ltd ::ZYDUS RECEIVES FINAL APPROVALS FROM USFDA FOR PHYTONADIONE TABLETS AND COLCHICINE TABLETS.PRODUCTS WILL BE MANUFACTURED AT GROUP’S FORMULATIONS MANUFACTURING FACILITY AT SEZ, AHMEDABAD.  Full Article

Indian shares skid on renewed fears of US-China trade spat

May 6 Indian shares fell on Monday, in line with tumbling Asian markets, after U.S. President Donald Trump threatened to raise tariffs on $200 billion worth of Chinese goods, casting doubts over talks this week that were largely expected to reach a trade accord.